Amneal Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B |
| Cost of revenue | $1.9B | $1.8B | $1.6B | $1.4B | $1.3B |
| Gross profit | $1.1B | $1.0B | $820.6M | $784.7M | $769.0M |
| Selling, general & administrative | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M |
| Research and development | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M |
| Pretax income | $139.2M | -$55.0M | -$40.3M | -$248.1M | $31.4M |
| Income tax expense | $11.3M | $18.9M | $8.5M | $6.7M | $11.2M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$270.6M | $13.2M |
| Balance Sheet | |||||
| Cash and equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M |
| Current assets | $1.9B | $1.6B | $1.4B | $1.4B | $1.5B |
| Total assets | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B |
| Current liabilities | $881.6M | $1.1B | $846.6M | $752.8M | $677.2M |
| Total debt | $2.7B | $2.5B | $2.5B | $2.6B | $2.7B |
| Stockholders' equity | -$70.8M | -$109.3M | $19.8M | $298.4M | $360.3M |
| Cash Flow Statement | |||||
| Cash from operations | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M |
| Depreciation and amortization | $57.3M | $62.6M | $66.2M | $68.1M | $60.7M |
| Stock-based compensation | $32.0M | $27.8M | $26.8M | $31.8M | $28.4M |
| Capital expenditure | $70.1M | $51.9M | $43.2M | $46.4M | $47.7M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M |
| Impairments | $0 | $0 | $30.8M | $13.0M | $710,000 |
Shares outstanding 319.0M · Free float 31.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.